title: Thromboxane synthase expression in renal transplant patients with rejection.
abstract: Thromboxane synthase (TS) catalyzes the formation of thromboxane (TxA2) in monocytes/macrophages, platelets, and various tissues. TxA2 is likely to play a role in graft dysfunction due to its vasoconstrictive and platelet aggregatory properties. We studied the expression of TS in 7 normal native kidneys, 29 consecutive renal allograft biopsies (performed for rising serum creatinine, n = 23, and delayed graft function, n = 6), and one transplant nephrectomy specimen with severe acute rejection. TS expression was determined by immunocytochemistry using a monoclonal antibody against human TS, Kon-7. Histologic grading of the transplant biopsy specimens was based on the Banff classification. The degree of TS staining was graded in the glomeruli, interstitium, tubules and vessels from 0 to 3+. Of 29 biopsies, 13 had chronic nephropathy (CN), 6 had acute rejection (AR) with chronic nephropathy (AR/CN), 4 had acute rejection (AR), and 6 had acute tubular necrosis (ATN). TS staining of native kidneys showed sporadic interstitial cells. The biopsy and transplant nephrectomy specimens showed significant staining, predominantly in the glomeruli and interstitium. Positively staining cells appeared to be of macrophage/monocyte lineage by morphology. The mean glomerular staining grade was significantly increased in specimens with AR (2.3 +/- 0.9) and the mean interstitial staining was increased in specimens with AR/CN (2.2 +/- 0.9). Follow-up renal function 6 months post-biopsy showed that patients with higher TS staining grades had a faster decline in graft function. In conclusion, TS expression is increased in patients with acute rejection with or without chronic nephropathy and is associated with more rapid deterioration in function.
authors.affiliation: Department of Medicine, University of Florida, Gainesville 32610-0224.
authors.forename: E L
authors.initials: EL
authors.lastname: Ramos
authors.forename: Y M
authors.initials: YM
authors.lastname: Barri
authors.forename: B P
authors.initials: BP
authors.lastname: Croker
authors.forename: W L
authors.initials: WL
authors.lastname: Clapp
authors.forename: J C
authors.initials: JC
authors.lastname: Peterson
authors.forename: C S
authors.initials: CS
authors.lastname: Wilcox
mesh_terms: D000328:Adult; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000201:enzymology* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000201:enzymology / Q000473:pathology; D016030:Kidney Transplantation; D008264:Macrophages / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013930:Thromboxane-A Synthase / Q000032:analysis*; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D013930:Thromboxane-A Synthase